- KalVista Pharmaceuticals (NASDAQ: KALV) received a “Market Perform” downgrade from Citigroup (NYSE: C), despite the strong early momentum of its new oral drug, EKTERLY.
- The downgrade precedes a significant corporate acquisition by Chiesi Group, valuing KalVista at approximately $1.9 billion, or $27.00 per share.
- A legal investigation is underway regarding the acquisition’s fairness and shareholder value, even as EKTERLY generates nearly $50 million in revenue and pushes KalVista’s stock to a new 52-week high of $26.70.
KalVista Pharmaceuticals (NASDAQ: KALV) is a biotechnology company that develops innovative treatments for rare diseases. It focuses on conditions like hereditary angioedema (HAE), a genetic disorder that causes swelling. The company recently launched a new oral drug named EKTERLY for on-demand treatment of HAE attacks, which has seen strong early momentum in the pharmaceutical market.
The investment firm Citigroup (NYSE: C) has issued a downgrade for KalVista’s stock. On April 29, 2026, the firm changed its rating from Outperform to Market Perform. This suggests that Citigroup believes the stock will now perform in line with the overall market. The stock price was $26.68 at the time of this announcement, impacting investor sentiment and stock market insights.
This rating change follows the news that Chiesi Group will acquire KalVista for $27.00 per share in cash. The corporate acquisition deal, valued at approximately $1.9 billion, was unanimously approved by both companies’ boards. Chiesi aims to expand its global portfolio of treatments for rare diseases through this strategic acquisition, highlighting its commitment to drug development.
Adding to the situation, the law firm Halper Sadeh LLC is investigating the sale. As highlighted by Business Wire, the investigation questions whether KalVista’s board secured the best possible price for its shareholders. It also examines if the sales process was fair and if all important information was disclosed, raising concerns about shareholder value and corporate governance.
Despite the downgrade, KalVista’s new drug EKTERLY shows a strong launch, generating nearly $50 million in revenue in about six months. This performance has helped the stock price surge 38.77% to $26.70, a new 52-week high. This brings the company’s market capitalization, or total value of all its shares, to $1.37 billion, reflecting significant growth in this biotechnology stock.
